Auxagen, Inc.

Olivette, MO

UEI
J74LH5EBZDA9
CAGE
47A01
Primary NAICS
813920 Professional Organizations
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Business
  • Woman Owned Small Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
7 Pricewoods Ln, Olivette, MO 63132, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A novel TGF- receptor antagonist to treat pulmonary fibrosis R43HL132679 National Institutes of Health $225,881
A therapeutic agent for radiation-induced lung fibrosis R43HL095261 National Institutes of Health $227,692
Novel therapeutic agents for diabetic ulcers R41DK078438 National Institutes of Health $182,189
Novel antagonists for ameliorating pulmonary fibrosis R41HL087463 National Institutes of Health $199,467
TGF-beta antagonists for accelerating wound healing R44AR052578 National Institutes of Health $998,034

Quick answers

Is Auxagen, Inc. registered in SAM.gov?

Yes. Auxagen, Inc.'s SAM.gov registration is active through August 14, 2027.

What is Auxagen, Inc.'s most recent federal award?

Auxagen, Inc.'s most recent federal grant award is A novel TGF- receptor antagonist to treat pulmonary fibrosis (R43HL132679), from National Institutes of Health, on June 1, 2016.

On GovTribe

See Auxagen, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login